Combined Ciprofloxacin and Tinidazole Therapy in the Treatment of Chronic Refractory Pouchitis
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 50 (4) , 498-508
- https://doi.org/10.1007/s10350-006-0828-3
Abstract
Management of chronic refractory pouchitis, a common cause for pouch failure with pouch resection or diversion, is often challenging. The aim of this study was to assess the efficacy and safety of a combination therapy of ciprofloxacin and tinidazole in patients with chronic refractory pouchitis compared with mesalamine therapy. Sixteen consecutive ulcerative colitis patients with chronic refractory pouchitis (disease>4 weeks and failure to respond to>4 weeks of single-antibiotic therapy) were treated with a four-week course of ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day. A historic cohort of ten consecutive patients with chronic refractory pouchitis treated with oral (4 g/day), enema (8 g/day), or suppository (1 g/day) mesalamine served as controls. The Pouchitis Disease Activity Index, clinical remission, clinical response, the Cleveland Global Quality of Life, the Irritable Bowel Syndrome-Quality of Life, and the Short Inflammatory Bowel Disease Questionnaires scores were calculated before and after therapy and compared between the two treatment groups. Patients taking ciprofloxacin and tinidazole had a significant reduction in the total Pouchitis Disease Activity Index scores and subscores and a significant improvement in quality-of-life scores (P< 0.002). For patients in the mesalamine group, there was a significant reduction in the total Pouchitis Disease Activity Index scores only. Patients in the antibiotic group had a greater reduction in the total Pouchitis Disease Activity Index scores and a greater improvement in the quality-of-life scores than those in the mesalamine group (P≤ 0.03). The rate of clinical remission and clinical response for the antibiotic group was 87.5 percent and 87.5 percent, respectively, and for the mesalamine group it was 50 percent and 50 percent, respectively (P= 0.069). Two patients in the antibiotic group (peripheral neuropathy and dysgeusia) developed adverse effects. Combination therapy with ciprofloxacin and tinidazole was generally well tolerated and was effective in treating patients with chronic refractory pouchitis.Keywords
This publication has 44 references indexed in Scilit:
- Comprehensive Evaluation of Inflammatory and Noninflammatory Sequelae of Ileal Pouch-Anal AnastomosesAmerican Journal of Gastroenterology, 2005
- An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule‐1, in the treatment of chronic, unremitting pouchitisAlimentary Pharmacology & Therapeutics, 2004
- Four‐week open‐label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitisAlimentary Pharmacology & Therapeutics, 2002
- Risk Factors and True Incidence of Pouchitis in Patients after Ileal Pouch–Anal AnastomosesWorld Journal of Surgery, 2000
- J ileal pouch–anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patientsBritish Journal of Surgery, 1998
- Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 1997
- Prospective Study of the Incidence, Timing, and Treatment of Pouchitis in 104 Consecutive Patients After Restorative ProctocolectomyArchives of Surgery, 1996
- Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.Gut, 1996
- IIeal Pouch-Anal Anastomoses Complications and Function in 1005 PatientsAnnals of Surgery, 1995
- Pouchitis following heal pouch-anal anastomosis: Definition, pathogenesis, and treatmentPublished by Elsevier ,1994